Suppr超能文献

吲哚拉明的心动过缓作用研究。

Investigations into the bradycardic action of indoramin.

作者信息

Lillie C, Harron D W, Kobinger W

出版信息

Arzneimittelforschung. 1985;35(1A):301-5.

PMID:4039170
Abstract

Indoramin is a selective alpha 1-antagonist which reduces blood pressure without reflex tachycardia and can cause a bradycardia. The direct bradycardic effect of indoramin was investigated in various isolated cardiac preparations as well as in the intact cat. In isolated guinea-pig atria indoramin reduced spontaneous atrial rate in concentrations similar to those that reduced maximal driving frequency but smaller than those reducing contractility (EC30 = 0.9, 1.3 and 5.2 micrograms/ml, respectively). In the isolated perfused electrically driven (2.5 Hz) guinea-pig heart, indoramin 1 microgram/ml mainly increased ST interval with no effect on QRS interval, higher concentrations (3 micrograms/ml) also increased the QRS interval. In anaesthetized cats indoramin 6 mg/kg i.v. reduced blood pressure and heart rate (increased cycle length), increased the ST interval and effective refractory period (measured by electrical stimuli from the right ventricle) but had little or no effect on the QRS interval and the diastolic stimulation threshold. With the 10 mg/kg dose the latter two parameters were increased. Analogous experiments with the antiarrhythmic drug mexiletine (class I) showed little changes in cycle length, effective refractory period and the ST interval, however, there was a marked increase in diastolic threshold. DL-sotalol, which as well as having a beta-adrenoceptor blocking action, also prolongs action potential duration (class III antiarrhythmic activity), had the same cardiac profile as indoramin. For both indoramin and sotalol a significant positive correlation was shown between increase in cycle length and increase in effective refractory period. It is suggested that indoramin exerts class III antiarrhythmic activity and that this property is responsible for the bradycardic action of the drug which is seen in doses that already markedly reduce blood pressure. In higher doses or concentrations indoramin also exerts class I antiarrhythmic activity which, however, does not contribute to the bradycardic effect.

摘要

吲哚拉明是一种选择性α1拮抗剂,可降低血压而无反射性心动过速,且可引起心动过缓。在各种离体心脏标本以及完整的猫身上研究了吲哚拉明的直接心动过缓作用。在离体豚鼠心房中,吲哚拉明降低自发心房率的浓度与降低最大驱动频率的浓度相似,但低于降低收缩性的浓度(EC30分别为0.9、1.3和5.2微克/毫升)。在离体灌注的电驱动(2.5赫兹)豚鼠心脏中,1微克/毫升的吲哚拉明主要增加ST段间期,对QRS间期无影响,更高浓度(3微克/毫升)也增加QRS间期。在麻醉猫中,静脉注射6毫克/千克的吲哚拉明可降低血压和心率(增加心动周期长度),增加ST段间期和有效不应期(通过右心室电刺激测量),但对QRS间期和舒张期刺激阈值影响很小或无影响。使用10毫克/千克剂量时,后两个参数增加。用抗心律失常药物美西律(I类)进行的类似实验显示心动周期长度、有效不应期和ST段间期变化很小,然而,舒张期阈值有明显增加。DL-索他洛尔除具有β肾上腺素受体阻断作用外,还可延长动作电位持续时间(III类抗心律失常活性),其心脏效应与吲哚拉明相同。对于吲哚拉明和索他洛尔,心动周期长度增加与有效不应期增加之间均显示出显著的正相关。提示吲哚拉明具有III类抗心律失常活性,且该特性是该药物在已能显著降低血压的剂量下出现心动过缓作用的原因。在更高剂量或浓度下,吲哚拉明还具有I类抗心律失常活性,但这对心动过缓效应无贡献。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验